Your Health, We Care
Cabozantinib is indicated for the treatment of patients with advanced renal cell carcinoma (RCC).
Cabozantinib, in combination with nivolumab, is indicated for the first-line treatment of patients with advanced RCC.
Cabozantinib is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
Cabozantinib is indicated for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible.
from FDA，2023.09
Cabozantinib (Cabometyx) was first approved by the FDA in 2012. It is a non‑spec···【more】
Release date：2026-03-20Recommended：54
On March 26, 2025, Exelixis, Inc. announced that the U.S. Food and Drug Administ···【more】
Release date：2026-03-20Recommended：74
Cabozantinib is a non-chemotherapy prescription medication classified as a tyros···【more】
Release date：2026-02-05Recommended：96
Cabozantinib has been approved for the treatment of various cancers.【more】
Release date：2026-01-06Recommended：87
Cabozantinib is a multi-kinase inhibitor that has demonstrated significant effic···【more】
Release date：2025-02-17Recommended：312
Cabozantinib is a multi-targeted tyrosine kinase inhibitor with a wide range of ···【more】
Release date：2025-02-17Recommended：284
Cabozantinib is a multi-targeted tyrosine kinase inhibitor that plays an importa···【more】
Release date：2025-02-13Recommended：284
Cabotinib is a multi-targeted tyrosine kinase inhibitor that has shown broad pot···【more】
Release date：2025-02-13Recommended：326
